KALA BIO, Inc. (KALA): Nasdaq/NYSE listing notice — Kala Pharma receives Nasdaq deficiency for MVPHS < $15M; faces delisting by Jan 2, 2023

KALA BIO, Inc.

On Dec 5, 2022, Nasdaq notified Kala that market value of publicly held shares was below $15M for 30 consecutive business days.
Company has 180 days (until June 5, 2023) to regain compliance; needs MVPHS >= $15M for 10 consecutive days.
Prior July 2022 deficiency for failing multiple Global Select Market standards; must cure by Jan 2, 2023 or face delisting.
Kala may transfer to Nasdaq Capital Market if compliance not regained; remains out of compliance with Rule 5450(b).

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

KALA BIO, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C), 5810(c)(3)(D)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(C), 5810(c)(3)(D)

Exact text from the filing

December 5, 2022, Kala Pharmaceuticals, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(b)(2)(C) (the “Minimum MVPHS Requirement”) for continued listing on the Nasdaq Global Select Market, as the market value of the Company’s publicly held shares was less than $15,000,000 for each of the previous 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Compan

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

KALA BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-125884

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.